vs
Medpace Holdings, Inc.（MEDP）与OneMedNet Corp（ONMD）财务数据对比。点击上方公司名可切换其他公司
Medpace Holdings, Inc.的季度营收约是OneMedNet Corp的796.0倍（$708.5M vs $890.0K）。Medpace Holdings, Inc.净利率更高（19.1% vs -352.8%，领先371.9%）。OneMedNet Corp同比增速更快（3323.1% vs 32.0%）。Medpace Holdings, Inc.自由现金流更多（$188.1M vs $-1.7M）。过去两年OneMedNet Corp的营收复合增速更高（89.4% vs 17.7%）
Medpace Holdings, Inc.是总部位于美国俄亥俄州辛辛那提的全球性临床研究机构（CRO），现有员工约6000人。公司采用全服务运营模式，可提供全球中心实验室、影像核心实验室、生物分析实验室服务，且在总部临床研究园区内设有I期临床试验单元。
OneMedNet Corp是一家总部位于美国的医疗科技企业，提供面向医学影像与患者健康信息的安全云数据共享及工作流解决方案，服务覆盖医疗机构、支付方及生命科学领域机构，核心运营市场为北美地区。
MEDP vs ONMD — 直观对比
营收规模更大
MEDP
是对方的796.0倍
$890.0K
营收增速更快
ONMD
高出3291.0%
32.0%
净利率更高
MEDP
高出371.9%
-352.8%
自由现金流更多
MEDP
多$189.8M
$-1.7M
两年增速更快
ONMD
近两年复合增速
17.7%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $708.5M | $890.0K |
| 净利润 | $135.1M | $-3.1M |
| 毛利率 | — | 20.7% |
| 营业利润率 | 21.6% | -353.4% |
| 净利率 | 19.1% | -352.8% |
| 营收同比 | 32.0% | 3323.1% |
| 净利润同比 | 15.5% | -32.3% |
| 每股收益（稀释后） | $4.65 | $-0.06 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MEDPONMD
| Q4 25 | $708.5M | $890.0K | ||
| Q3 25 | $659.9M | $177.0K | ||
| Q2 25 | $603.3M | $155.0K | ||
| Q1 25 | $558.6M | $137.0K | ||
| Q4 24 | $536.6M | $26.0K | ||
| Q3 24 | $533.3M | $142.0K | ||
| Q2 24 | $528.1M | $227.0K | ||
| Q1 24 | $511.0M | $248.0K |
净利润MEDPONMD
| Q4 25 | $135.1M | $-3.1M | ||
| Q3 25 | $111.1M | $-741.0K | ||
| Q2 25 | $90.3M | $3.0M | ||
| Q1 25 | $114.6M | $-1.9M | ||
| Q4 24 | $117.0M | $-2.4M | ||
| Q3 24 | $96.4M | $-2.1M | ||
| Q2 24 | $88.4M | $-3.6M | ||
| Q1 24 | $102.6M | $-2.1M |
毛利率MEDPONMD
| Q4 25 | — | 20.7% | ||
| Q3 25 | — | -125.4% | ||
| Q2 25 | — | -155.5% | ||
| Q1 25 | — | -163.5% | ||
| Q4 24 | — | -100.0% | ||
| Q3 24 | — | -59.2% | ||
| Q2 24 | — | -44.9% | ||
| Q1 24 | — | -27.8% |
营业利润率MEDPONMD
| Q4 25 | 21.6% | -353.4% | ||
| Q3 25 | 21.5% | -1262.7% | ||
| Q2 25 | 20.9% | -1331.0% | ||
| Q1 25 | 20.3% | -1623.4% | ||
| Q4 24 | 23.4% | -10438.5% | ||
| Q3 24 | 21.1% | -1645.1% | ||
| Q2 24 | 19.9% | -1081.1% | ||
| Q1 24 | 20.4% | -847.2% |
净利率MEDPONMD
| Q4 25 | 19.1% | -352.8% | ||
| Q3 25 | 16.8% | -418.6% | ||
| Q2 25 | 15.0% | 1923.9% | ||
| Q1 25 | 20.5% | -1388.3% | ||
| Q4 24 | 21.8% | -9126.9% | ||
| Q3 24 | 18.1% | -1449.3% | ||
| Q2 24 | 16.7% | -1581.1% | ||
| Q1 24 | 20.1% | -850.4% |
每股收益（稀释后）MEDPONMD
| Q4 25 | $4.65 | $-0.06 | ||
| Q3 25 | $3.86 | $-0.01 | ||
| Q2 25 | $3.10 | $0.07 | ||
| Q1 25 | $3.67 | $-0.06 | ||
| Q4 24 | $3.67 | $-0.07 | ||
| Q3 24 | $3.01 | $-0.07 | ||
| Q2 24 | $2.75 | $-0.14 | ||
| Q1 24 | $3.20 | $-0.08 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $497.0M | $585.0K |
| 总债务越低越好 | — | $220.0K |
| 股东权益账面价值 | $459.1M | $-3.0M |
| 总资产 | $2.0B | $2.2M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资MEDPONMD
| Q4 25 | $497.0M | $585.0K | ||
| Q3 25 | $285.4M | $149.0K | ||
| Q2 25 | $46.3M | $122.0K | ||
| Q1 25 | $441.4M | $144.0K | ||
| Q4 24 | $669.4M | $172.0K | ||
| Q3 24 | $656.9M | $1.9M | ||
| Q2 24 | $510.9M | $407.0K | ||
| Q1 24 | $407.0M | $174.0K |
总债务MEDPONMD
| Q4 25 | — | $220.0K | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $2.3M | ||
| Q4 24 | — | $2.3M | ||
| Q3 24 | — | $2.3M | ||
| Q2 24 | — | $2.4M | ||
| Q1 24 | — | — |
股东权益MEDPONMD
| Q4 25 | $459.1M | $-3.0M | ||
| Q3 25 | $293.6M | $-3.9M | ||
| Q2 25 | $172.4M | $-3.8M | ||
| Q1 25 | $593.6M | $-16.6M | ||
| Q4 24 | $825.5M | $-15.9M | ||
| Q3 24 | $881.4M | $-14.3M | ||
| Q2 24 | $763.6M | $-19.2M | ||
| Q1 24 | $671.5M | $-15.7M |
总资产MEDPONMD
| Q4 25 | $2.0B | $2.2M | ||
| Q3 25 | $1.8B | $1.5M | ||
| Q2 25 | $1.6B | $2.3M | ||
| Q1 25 | $1.9B | $1.7M | ||
| Q4 24 | $2.1B | $3.7M | ||
| Q3 24 | $2.1B | $4.4M | ||
| Q2 24 | $1.9B | $1.0M | ||
| Q1 24 | $1.8B | $750.0K |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $192.7M | $-1.7M |
| 自由现金流经营现金流 - 资本支出 | $188.1M | $-1.7M |
| 自由现金流率自由现金流/营收 | 26.6% | -193.0% |
| 资本支出强度资本支出/营收 | 0.6% | 0.6% |
| 现金转化率经营现金流/净利润 | 1.43× | — |
| 过去12个月自由现金流最近4个季度 | $681.9M | — |
8季度趋势，按日历期对齐
经营现金流MEDPONMD
| Q4 25 | $192.7M | $-1.7M | ||
| Q3 25 | $246.2M | $-1.6M | ||
| Q2 25 | $148.5M | $-2.3M | ||
| Q1 25 | $125.8M | $-1.9M | ||
| Q4 24 | $190.7M | $-2.0M | ||
| Q3 24 | $149.1M | $-1.9M | ||
| Q2 24 | $116.4M | $-1.5M | ||
| Q1 24 | $152.7M | $-1.5M |
自由现金流MEDPONMD
| Q4 25 | $188.1M | $-1.7M | ||
| Q3 25 | $235.5M | — | ||
| Q2 25 | $142.4M | $-2.3M | ||
| Q1 25 | $115.8M | $-2.0M | ||
| Q4 24 | $183.0M | $-2.0M | ||
| Q3 24 | $138.5M | $-1.9M | ||
| Q2 24 | $103.5M | $-1.5M | ||
| Q1 24 | $147.2M | $-1.6M |
自由现金流率MEDPONMD
| Q4 25 | 26.6% | -193.0% | ||
| Q3 25 | 35.7% | — | ||
| Q2 25 | 23.6% | -1475.5% | ||
| Q1 25 | 20.7% | -1425.5% | ||
| Q4 24 | 34.1% | -7811.5% | ||
| Q3 24 | 26.0% | -1346.5% | ||
| Q2 24 | 19.6% | -663.9% | ||
| Q1 24 | 28.8% | -626.2% |
资本支出强度MEDPONMD
| Q4 25 | 0.6% | 0.6% | ||
| Q3 25 | 1.6% | 0.0% | ||
| Q2 25 | 1.0% | 1.9% | ||
| Q1 25 | 1.8% | 3.6% | ||
| Q4 24 | 1.4% | 134.6% | ||
| Q3 24 | 2.0% | 6.3% | ||
| Q2 24 | 2.4% | 0.4% | ||
| Q1 24 | 1.1% | 2.4% |
现金转化率MEDPONMD
| Q4 25 | 1.43× | — | ||
| Q3 25 | 2.22× | — | ||
| Q2 25 | 1.65× | -0.77× | ||
| Q1 25 | 1.10× | — | ||
| Q4 24 | 1.63× | — | ||
| Q3 24 | 1.55× | — | ||
| Q2 24 | 1.32× | — | ||
| Q1 24 | 1.49× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MEDP
| Metabolic | $249.8M | 35% |
| Oncology | $195.9M | 28% |
| Other | $88.3M | 12% |
| Central Nervous System | $73.2M | 10% |
| Cardiology | $63.0M | 9% |
| Antiviral And Anti Infective | $38.3M | 5% |
| Related Party | $10.3M | 1% |
ONMD
暂无分部数据
